FDA accepts BridgeBio’s application for potential first limb-girdle muscular dystrophy drug

The FDA’s priority review acceptance of BridgeBio’s BBP-418 is another step toward what William Blair previously dubbed a “diversified commercial portfolio.” It also adds to the rapidly building momentum in muscular dystrophy more broadly.